Antidementia drug prescription sources and patterns after the diagnosis of dementia in Germany: Results of a claims data-based 1-year follow-up

International Clinical Psychopharmacology

Volumn 26, Issue 4, 2011, Pages 225-231

  Van Den Bussche, Hendrik ^a   Kaduszkiewicz, Hanna ^a   Koller, Daniela ^c   Eisele, Marion ^a   Steinmann, Susanne ^b   Glaeske, Gerd ^c   Wiese, Birgitt ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF BREMEN   (Germany)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Dementia; Drug prescription; Memantine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HERBACEOUS AGENT; MEMANTINE; NOOTROPIC AGENT; RIVASTIGMINE;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; COMORBIDITY; CONSULTATION; DEMENTIA; FEMALE; FOLLOW UP; GERMANY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MULTIINFARCT DEMENTIA; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; URBAN AREA;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMBULATORY CARE; CHOLINESTERASE INHIBITORS; COMORBIDITY; DATABASES, FACTUAL; DEMENTIA; DEMENTIA, VASCULAR; DRUG PRESCRIPTIONS; FEMALE; FOLLOW-UP STUDIES; GERMANY; GUIDELINE ADHERENCE; HUMANS; MALE; MEDICATION ADHERENCE; MEMANTINE; NATIONAL HEALTH PROGRAMS; NOOTROPIC AGENTS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, PRIMARY CARE; PLANT PREPARATIONS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RURAL POPULATION; SPECIALIZATION; URBAN POPULATION;

EID: 80051544015     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328344c600     Document Type: Article

References (27)

1. Bickel H (2001). Dementias in old age: Estimates of prevalence and costs of care (German). Z Gerontol Geriatr 34:108-115. (Pubitemid 32428204)
2. Bohlken J, Selke GW, van den Bussche H. Prescription of antidementia drugs in urban and rural areas (2011). Comparison between metropolitan areas and rural states in Germany. Psychiat Prax (In Press).
3. Busse R, Riesberg A (2004). Health care systems in transition: Germany. Copenhagen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies.
4. DiMatteo MR, Lepper HS, Croghan TW (2000). Depression is a risk factor for noncompliance with medical treatment. Arch Intern Med 160:2101-2107.
5. Drug Commission of the German Medical Association, 2004. Dementia. Drug prescription in practice. Therapeutic guidelines of the Drug Commission of the German Medical Association. German [online]. Available at: www.akdae.de/ Arzneimitteltherapie/TE/Archiv/Demenz.pdf [Accessed 17 November 2010].
6. Dybicz SB, Keohane DJ, Erwin GE, McRae T, Shah SN (2006). Patterns of cholinesterase-inhibitor use in the nursing home setting: a rertrospective analysis. Am J Geriatr Pharamcother 4:154-160. (Pubitemid 44057811)
7. Eisele M, Van den Bussche H, Koller D, Wiese B, Kaduszkiewicz H, Glaeske G, et al. (2010). Utilization patterns of ambulatory medical care before and after the diagnosis of dementia in Germany - results of a case-control study. Dement Geriatr Cogn Disord 29:475-483.
8. Evaluations-Koordinierungsstelle Integrierte Versorgung, 2010. EKIV Newsletter 3/2010. Freiburg [online]. Available at: www.ekiv.org/pdf/EKIV- Newsletter-2010-3-English-version.pdf [Accessed 17 November 2010].
9. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. (2005). Global prevalence of dementia: a delphi consensus study. Lancet 366:2112-2117. (Pubitemid 41797645)
10. Fricke U, Gü nther J, Zawinel A (2010). Anatomical-therapeutic- chemical classification with daily doses for the German drug market. Methodology of the ATC-classification. German [online]. Wissenschaftliches Institut der AOK, Bonn. Available at: http://wido.de/arz-atcddd-klassifi.html [Accessed 15 November 2010].
11. Gadzhanova S, Roughead L, Mackson J (2010). GEK-report on ambulatory medical care (German). Aust New Zeal J Psychiatr 44:469-474.
12. Gardette V, Andrieu S, Lapeyre-Mestre M, Coley N, Cantet C, Ousset PJ, et al. (2010). Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study. CNS Drugs 24:431-442. doi: 10.2165/11318010
13. German Society for Psychiatry and Psychotherapy and German Society for Neurology, 2010. S3-Guideline Dementias. German [online]. Available at: http://media.dgppn.de/mediadb/media/dgppn/pdf/leitlinien/s3-leitlinie-demenzlf. pdf [Accessed 20 April 2010].
14. Gemeinsamer Bundesausschuss, 2010. Directive of the Federal Joint Committee on the prescriptiopn of drugs in the statutory health insurance system Attachment III. German [online]. Available at: www.g-ba.de/informationen/ richtlinien/anlage/zur-richtlinie/3/#16/ [Accessed 15 November 2010].
15. Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand SL, Rochon PA (2009). Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med 169:867-73.
16. Grobe T, Dö rning H, Schwartz F (2006). GEK-Report ambulant-ärztliche Versorgung. St Augustin: Asgard Verlag; German.
17. Hernandez RK, Farwell W, Cantor MD, Lawler EV (2009). Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system. J Am Geriatr Soc 57:1997-2003.
18. Herrmann N, Binder C, Dalziel W, Smyth S, Canacho F (2009). Persistence with cholinesterase inhibitor therapy for dementia. Drugs Aging 26:403-407.
19. Hoffmann F, Van den Bussche H, Glaeske G, Kaduszkiewicz H (2010). Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany. Int Clin Psychopharmacol 25:29-36.
20. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van Bussche HD (2005). Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 331:321-323. (Pubitemid 41113141)
21. Klose J, Rehbein E, Uhlemann T (2007). Physician atlas. Data on density of physicians in ambulatory medical care (German). Bonn: Wissenschaftliches Institut der AOK; German.
22. Koller D, Eisele M, Kaduszkiewicz H, Kemper C, Schö n G, Steinmann S, et al. (2010). Ambulatory health services care utilization in demented patients - is there a urban-rural difference? J Health Geograph 9:59.
23. Mauskopf JA, Paramore C, Lee WC, Snyder EH (2005). Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm 11:231-239.
24. Park-Wyllie LY, Mamdani MM, Li P, Gill SS, Laupacis A, Juurlink D (2009). Cholinesterase inhibitors and hospitalization for bradycardia: a population based study. PLoS Med 6:e1000157. 10.1371/journal.pmed.1000157.
25. Suh DC, Thomas SK, Valiyeva E, Arcona S, Vo L (2005). Drug persistency of two cholinesterase Inhibitors. Drugs Aging 22:695-707.
26. Vidal JS, Lacombe JM, Dartigues JF, Pasquier F, Robert P, Tzourio C, Alpérovitch A (2008). Mementine therapy for Alzheimer Disease in real-world practice. Alzheimer Dis Assoc Disord 22:125-130.
27. van den Bussche H, Hanna Kaduszkiewicz H (2005). Prescription pattern and effectiveness perception of anti-dementia drugs. A comparison between general practitioners, neurologists and psychiatrists. Nervenheilkunde 24:485-492. (Pubitemid 41274822)